SCHEMBL11207707

SCHEMBL11207707

CC(C)CCCCCCNCC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.43
HRH3 Q9Y5N1 2/20 0.43
LMNA P02545 1/20 0.42
EPHX1 P07099 1/20 0.35
GRIN1 Q05586 2/20 0.34
GRIN2A Q12879 2/20 0.34
ANPEP P15144 2/20 0.33
ADH1B P00325 2/20 0.33
ADH1C P00326 2/20 0.33
ADH1A P07327 2/20 0.33
ERAP2 Q6P179 1/20 0.33
PKM P14618 1/20 0.33
CA2 P00918 1/20 0.33
KDM4C Q9H3R0 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
KDM4A O75164 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22861967 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL21106835 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL22856504 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL23695755 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL9193203 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL23806605 1.00 HRH4 (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL13879290 0.97 LMNA (0.43) HRH4HRH3LMNAEPHX1GRIN1
SCHEMBL13879291 0.90 LMNA (0.39) HRH4HRH3LMNAANPEPADH1B
SCHEMBL2483497 0.89 HRH4 (0.48) HRH4HRH3EPHX1GRIN1GRIN2A
SCHEMBL24379824 0.89 HRH4 (0.48) HRH4HRH3EPHX1GRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 US disclosed
US-20210002296-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-01-07 US disclosed
EP-0031924-B1 USE OF ALCANOL-AMINE SALTS OF CYCLIC AMIDOCARBOXYLIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS BASF Aktiengesellschaft (DE) 1983-05-18 EP disclosed
EP-0031924-A1 Use of alcanol-amine salts of cyclic amidocarboxylic acids as corrosion inhibitors in aqueous systems BASF Aktiengesellschaft (DE) 1981-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002296-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 HRH4 4276/4885HRH3 4266/4885LMNA 2563/4885
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 HRH4 4261/4885HRH3 4228/4885LMNA 2219/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HRH4 3886/4885HRH3 3631/4885LMNA 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.